PGEN
Precigen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.10
−0.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 85.7M | 9.7M | 3.9M | 6.2M | 26.9M |
| Cost of Revenue | 8.9M | 6.1M | 4.3M | 6.1M | 6.3M |
| Gross Profit | 76.8M | 3.6M | (342.0K) | 106.0K | 20.6M |
| Operating Expenses | |||||
| R&D Expense | 31.3M | 40.1M | 53.1M | 48.6M | 47.2M |
| SG&A Expense | 84.9M | 70.1M | 41.3M | 40.4M | 48.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 40.3M | 10.8M | 1.1M |
| Total Operating Expenses | 116.3M | 110.2M | 134.7M | 99.9M | 96.3M |
| Cost and Expenses | 125.2M | 116.3M | 139.0M | 106.0M | 102.6M |
| Operating Income (EBIT) | (39.5M) | (106.6M) | (135.0M) | (99.8M) | (75.7M) |
| Non-Operating | |||||
| Interest Income | 2.6M | 3.2M | 1.4M | 3.2M | 133.0K |
| Interest Expense | 9.7M | 3.9M | 6.0K | 468.0K | 6.8M |
| Net Interest Income | (7.1M) | (652.0K) | 1.4M | 2.8M | (6.6M) |
| Other Non-Op Income/Expense | (118.2M) | (144.0M) | 7.0M | 3.4M | (4.2M) |
| Non-Operating Income (excl Interest) | 108.5M | 140.2M | (7.0M) | (3.9M) | (2.5M) |
| EBT (Pre-Tax Income) | (157.7M) | (250.6M) | (128.0M) | (96.4M) | (80.0M) |
| Income Tax Expense | — | 3.0K | (1.8M) | (458.0K) | (189.0K) |
| Bottom Line | |||||
| Net Income | (157.7M) | (250.6M) | (126.2M) | (95.9M) | 28.3M |
| Earnings from Cont. Ops | (157.7M) | (250.6M) | (126.2M) | (95.9M) | (79.8M) |
| Earnings from Discont. Ops | — | — | — | — | 108.1M |
| Bottom Line Net Income | (336.7M) | (429.6M) | (126.2M) | (95.9M) | (79.8M) |
| Per Share | |||||
| Basic EPS | ($1.13) | ($1.41) | ($0.47) | ($0.39) | ($0.33) |
| Diluted EPS | ($1.14) | ($1.41) | ($0.47) | ($0.39) | ($0.40) |
| Revenue Per Share | $0.24 | $0.03 | $0.01 | $0.03 | $0.13 |
| Shares | |||||
| Basic Shares Outstanding | 356.9M | 304.7M | 267.7M | 244.5M | 200.4M |
| Diluted Shares Outstanding | 413.7M | 304.7M | 267.7M | 244.5M | 200.4M |
| Profitability Metrics | |||||
| EBITDA | (144.9M) | (243.6M) | (123.5M) | (89.2M) | (62.4M) |
| D&A | 3.0M | 3.2M | 4.5M | 6.7M | 10.8M |
| EBIT | (148.0M) | (246.8M) | (128.0M) | (95.9M) | (73.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026